City of South San Francisco header
File #: 24-332    Name:
Type: Staff Report Status: Agenda Ready - Administrative Business
File created: 3/26/2024 In control: Planning Commission
On agenda: 4/18/2024 Final action:
Title: Report regarding submission of the 2023 Genentech Annual Report for Planning Commission consideration. (Billy Gross, Principal Planner)
Attachments: 1. 2023 Genentech Master Plan Annual Report
Date Ver.Action ByActionResultAction DetailsMeeting DetailsVideo
No records to display.

Title

Report regarding submission of the 2023 Genentech Annual Report for Planning Commission consideration. (Billy Gross, Principal Planner)

 

label

RECOMMENDATION

Recommendation

Staff recommends that the Planning Commission review and accept the 2023 Genentech Annual Report pursuant to Chapter 20.260 of the South San Francisco Municipal Code.

 

Body

BACKGROUND/DISCUSSION

The Genentech Master Plan, which was updated in 2020, guides development of the Genentech 207-acre campus through the next planning horizon (anticipated to be 20 years or more). South San Francisco Municipal Code (SSFMC) Section 20.260.006 (Genentech Master Plan District Administration) requires that the Planning Commission reviews development activity within the Genentech campus at least once a year, and requires that Genentech submits an annual report which contains the following components, as appropriate:

                     Status of facility-wide improvements

                     Progress in completing the required tasks and benchmarks described in the implementation plan and / or Development Agreement

                     Anticipated new construction or renovation projects

                     An update on transportation and parking needs

                     An update on mobile vendor (employee amenity) activities on the Genentech campus

                     An update of the facility-wide transportation demand management (TDM) program

                     Projected changes in the facility usage and requirements

                     Advance notice of any proposed changes to the facility-wide development standards or design guidelines

                     Notice of any changes that have been made to the facility master plan since the most recent annual report.

 

Campus Development and Buildout

Genentech has submitted an Annual Report for 2023 (Attachment 1 to this staff report), for Planning Commission review and consideration. The Annual Report provides updates on all the required components. The Annual Report notes that construction activity in 2023 focused on upgrades and maintenance of existing facilities, engagement of several major construction projects to be delivered in 2024, and tenant improvements to B86 (a leased lab facility at 751 Gateway Blvd). No net new square footage was added to the campus.

 

Transportation Demand Management and Parking

Genentech continued to see improvements to its TDM program post-pandemic. The expectation that employees would be on campus a minimum of 50% of the time continued in 2023, reflecting a new hybrid work environment. The percentage of alternative transportation modes to the campus was just over 39 percent; this is a continued improvement over pandemic-related years and is closer to Genentech’s pre-pandemic average of 40-42 percent alternative transportation modes. If remote work or absence are also included, the overall mode split rises to 60 percent.

Traffic cordon counts and parking surveys were conducted in mid-November 2023. The cordon count indicates that Genentech is consistent with the required trip cap, which limits AM single-occupancy vehicle (SOV) peak hour trips to 5,216. The cordon count reported an average of 3,661 AM peak hour SOV trips, well below the trip cap limit. A parking inventory indicates that parking on the Genentech campus was at 70% occupancy.

CONCLUSION

Staff finds that the submitted report is consistent with the reporting requirements and recommends that the Planning Commission accept the 2023 Genentech Annual Report.

 

Attachment

1.                     2023 Genentech Annual Report